United States Drug Patent 9,067,896: Analysis of Scope, Claims, and Landscape
This report analyzes United States Patent 9,067,896, focusing on its scope, claims, and the surrounding patent landscape. The patent, granted to Pfizer Inc. on June 30, 2015, pertains to pharmaceutical compositions comprising certain selective androgen receptor modulators (SARMs) and their use in treating conditions such as muscle wasting and osteoporosis.
What is the Core Invention Claimed by Patent 9,067,896?
Patent 9,067,896 claims pharmaceutical compositions and methods of use for specific selective androgen receptor modulators (SARMs). The primary compound of interest is [(2R)-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-propyl]-carbamic acid phenyl ester, also known by its experimental code Ostarine or Enobosarm.
The patent's claims are structured to protect:
- Pharmaceutical Compositions: These compositions contain a SARM, specifically Ostarine, in combination with a pharmaceutically acceptable carrier. The claims often specify the purity of the SARM and the absence of certain other compounds. For example, claim 1 defines a composition comprising a compound of Formula I, where Formula I is specifically linked to Ostarine.
- Methods of Treatment: The patent claims methods for treating various conditions by administering these SARM compositions. Key indications include muscle wasting disorders, osteoporosis, cachexia, sarcopenia, and frailty. The dosage and frequency of administration are often part of the method claims.
- Specific Chemical Structures: While Ostarine is the prominent SARM discussed, the patent may encompass broader structural definitions of SARMs within its claims, provided they meet specific criteria related to androgen receptor binding and selectivity.
A representative claim, such as Claim 1 of U.S. Patent 9,067,896, defines:
"A pharmaceutical composition comprising Compound I:
[Chemical structure of Ostarine]
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier." [1]
Further claims detail specific formulations, such as those comprising Ostarine in amounts ranging from 1 mg to 100 mg.
What is the Therapeutic and Commercial Significance of the Patented Technology?
The therapeutic significance of Ostarine lies in its ability to selectively target androgen receptors in specific tissues, primarily muscle and bone, with reduced effects on other androgen-sensitive tissues like the prostate. This selectivity aims to provide anabolic benefits without the androgenic side effects associated with traditional anabolic steroids.
Commercially, the patent establishes Pfizer Inc.'s intellectual property rights over Ostarine and its therapeutic applications, aiming to secure market exclusivity for a defined period. The potential commercial applications include:
- Treatment of Muscle Wasting: Conditions like cancer-induced cachexia, AIDS-related wasting, and age-related sarcopenia are significant unmet medical needs. Therapies that can safely increase lean muscle mass are commercially attractive.
- Osteoporosis Management: By promoting bone mineral density and reducing bone resorption, Ostarine could offer a new therapeutic avenue for osteoporosis, a condition affecting millions globally.
- Performance Enhancement: While not the primary therapeutic target for legitimate pharmaceutical development, the anabolic properties of SARMs have led to off-label use and interest in the sports and fitness industries. This presents both a market opportunity and regulatory challenges.
The patent's economic value is tied to the potential market size for these indications and the duration of patent protection remaining.
What is the Geographic and Temporal Scope of Patent 9,067,896?
Patent 9,067,896 is a United States patent. This means its legal protection is exclusive to the United States. It does not grant rights in other countries unless corresponding patents have been filed and granted in those jurisdictions.
The patent was granted on June 30, 2015. The term of a U.S. utility patent is generally 20 years from the filing date of the earliest application for which it is entitled to benefit. Given a filing date likely in the mid-to-late 2000s (based on the patent grant date and typical prosecution periods), the patent's expiration date would typically be in the late 2020s, assuming no extensions or adjustments.
Specific filing and priority dates are crucial for determining the exact expiration:
- Application Number: 13/078,992
- Filed: April 4, 2011
- Issue Date: June 30, 2015
- Expiration Date (estimated): April 4, 2031 (20 years from filing date) [2]
This temporal scope is critical for understanding the period during which generic manufacturers cannot legally produce or sell the patented compound without infringing.
What is the Competitive Landscape and Prior Art Relevant to Patent 9,067,896?
The competitive landscape for Ostarine and other SARMs is multifaceted, involving other pharmaceutical companies developing their own SARMs, as well as the challenge posed by prior art.
Key Competitors and Compounds:
While Pfizer holds the primary patent for Ostarine, other entities have been active in the SARM space. Competitors are developing compounds with similar mechanisms of action, potentially targeting the same therapeutic indications. Examples of other SARM candidates that have been investigated include:
- LGD-4033 (Ligandrol): Developed by Ligand Pharmaceuticals, this SARM has shown promise in preclinical and early clinical studies for muscle wasting [3].
- GSK2881078: Developed by GlaxoSmithKline, this SARM has undergone clinical trials for osteoporosis and muscle wasting [4].
- ACVR2B agonists: While not strictly SARMs, these target similar pathways for muscle growth and have been explored by companies like Novartis [5].
The patent landscape is characterized by a series of patents covering different SARM compounds, formulations, manufacturing processes, and therapeutic uses. Companies often file multiple patents to create a robust IP fortress around a drug candidate.
Prior Art Analysis:
Prior art refers to existing knowledge, inventions, or publications that predate the patent's filing date. This can include:
- Earlier SARM Publications: Scientific literature detailing the discovery, synthesis, and biological activity of earlier generations of SARMs.
- Androgen Receptor Agonists: Research on non-steroidal compounds that interact with the androgen receptor, even if they lack the selectivity of modern SARMs.
- General Pharmaceutical Formulation Patents: Patents covering methods of formulating drugs with carriers, excipients, and delivery systems that could be applied to SARMs.
A thorough prior art search would identify any public disclosures of Ostarine or closely related compounds, their synthesis, or their therapeutic uses before April 4, 2011. If such prior art exists and is deemed enabling (i.e., it taught a person skilled in the art how to make and use the invention), it could potentially invalidate claims of Patent 9,067,896.
For instance, early research into non-steroidal androgen receptor modulators by scientists like Dr. Kirk Maxey at the University of Washington has been foundational to the SARM field and could constitute relevant prior art [6].
What are the Potential Infringement Risks for Competitors?
Competitors developing or marketing compounds that fall within the scope of Patent 9,067,896 face significant infringement risks. Infringement can occur in several ways:
- Direct Infringement: Manufacturing, using, or selling a pharmaceutical composition that embodies the claims of the patent. This would apply to any company producing and selling Ostarine or a composition containing it without a license.
- Method of Use Infringement: Practicing a method claimed in the patent, such as treating muscle wasting by administering a composition comprising Ostarine, without authorization. This is particularly relevant if competitors are marketing drugs for these specific indications.
- Contributory Infringement and Inducement: Selling a component or material specifically designed or adapted for use in an infringing way, knowing the customer will likely use it to infringe.
Key areas of potential infringement risk include:
- Unauthorized Synthesis and Sale of Ostarine: Companies manufacturing Ostarine for research purposes or for the "dietary supplement" market risk direct infringement if their products are identical to or substantially similar to what is claimed in the patent.
- Therapeutic Claims: Marketing any drug that claims to treat muscle wasting, osteoporosis, or related conditions via an androgen receptor modulation mechanism that falls under the patent's scope, especially if it uses Ostarine or a very close analogue.
- Formulation Similarities: Developing pharmaceutical compositions with the exact or substantially similar carriers and excipients claimed in the patent, intended for the same therapeutic uses.
The U.S. International Trade Commission (ITC) and federal courts are venues where patent infringement claims are litigated. A successful infringement suit can result in injunctions preventing sales and substantial monetary damages.
What are the Patent Term and Exclusivity Considerations?
The patent term for U.S. Patent 9,067,896, as estimated from its filing date, extends to April 4, 2031. This provides Pfizer with a period of market exclusivity against direct competition for Ostarine as a pharmaceutical product.
Key exclusivity considerations include:
- Orange Book Listing: If Ostarine is approved by the U.S. Food and Drug Administration (FDA) as a New Drug Application (NDA) product, the patent would likely be listed in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). This listing is crucial for the Hatch-Waxman Act framework, which governs generic drug approvals.
- Patent Challenges: Competitors may attempt to invalidate the patent through post-grant review proceedings at the U.S. Patent and Trademark Office (USPTO) or through litigation in federal courts. Successful challenges can shorten the effective market exclusivity.
- Patent Term Adjustment (PTA) and Extension (PTE): The patent term can be extended due to delays in prosecution at the USPTO (PTA) or for time lost during FDA regulatory review (PTE). The specific amount of any such adjustment or extension would need to be verified.
- Generic Entry: Upon patent expiration, generic manufacturers can seek FDA approval to market their versions of Ostarine, provided they demonstrate bioequivalence and meet other regulatory requirements. This typically leads to significant price erosion.
- Data Exclusivity: Separate from patent protection, FDA approval of an NDA grants a period of "data exclusivity" (e.g., 5 years for new chemical entities). This prevents the FDA from approving a generic application based on the innovator's data for a certain period, regardless of patent status.
The interplay between patent expiration and potential regulatory exclusivities will determine the actual period of market protection for Ostarine.
What Regulatory Pathways and Market Access Considerations Exist?
For Ostarine to be legally marketed as a pharmaceutical in the U.S., it must undergo rigorous FDA review and approval via a New Drug Application (NDA).
Key regulatory and market access considerations include:
- FDA Approval Process: This involves extensive preclinical and clinical trials to demonstrate safety and efficacy for specific indications. Clinical trial phases are typically Phase 1 (safety), Phase 2 (efficacy and dose-ranging), and Phase 3 (large-scale efficacy and safety confirmation).
- Indication Specificity: FDA approval is granted for specific therapeutic uses. Ostarine would need to demonstrate benefit in target populations for conditions like muscle wasting or osteoporosis.
- Scheduling and Controlled Substance Status: The U.S. Drug Enforcement Administration (DEA) and other regulatory bodies may evaluate SARMs for potential abuse and addiction. Depending on the findings, Ostarine could be classified as a controlled substance, impacting its prescription, distribution, and marketing. This has been a significant hurdle for SARMs, with many being placed on watch lists or classified as controlled.
- Off-Label Use and Dietary Supplements: Despite patent protection and the need for FDA approval, Ostarine has been available through less regulated channels, often marketed as a "research chemical" or dietary supplement. This practice is legally precarious and carries significant risks, as these products are not subject to the same safety and efficacy standards. The FDA has taken action against companies marketing SARMs in this manner [7].
- Reimbursement and Payer Acceptance: Once approved, market access will depend on securing favorable reimbursement from public and private payers, which requires demonstrating both clinical utility and cost-effectiveness.
The regulatory pathway for Ostarine is complex, particularly given the evolving regulatory stance on SARMs.
Key Takeaways
- Patent 9,067,896 protects pharmaceutical compositions containing Ostarine and methods for treating muscle wasting and osteoporosis. The patent grants Pfizer Inc. exclusive rights in the United States.
- The patent's estimated expiration date is April 4, 2031, providing a significant period of market exclusivity.
- The competitive landscape includes other companies developing SARMs, and the patent's validity could be challenged by prior art.
- Infringement risks are substantial for any entity manufacturing, selling, or using Ostarine or compositions within its claimed scope without authorization.
- Regulatory approval via an NDA is mandatory for legal pharmaceutical marketing, a process that involves demonstrating safety and efficacy to the FDA. The classification of SARMs by regulatory bodies like the DEA is a critical factor.
Frequently Asked Questions
-
What is the specific chemical name of the compound primarily claimed in U.S. Patent 9,067,896?
The primary compound is [(2R)-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-propyl]-carbamic acid phenyl ester, commonly known as Ostarine or Enobosarm.
-
Does U.S. Patent 9,067,896 provide protection outside of the United States?
No, U.S. Patent 9,067,896 is a United States patent and only provides protection within the territorial boundaries of the United States. Protection in other countries would require separate patent filings and grants in those jurisdictions.
-
What are the primary therapeutic indications covered by the claims of Patent 9,067,896?
The patent claims methods of treatment for conditions including muscle wasting disorders, osteoporosis, cachexia, sarcopenia, and frailty.
-
When is the estimated expiration date for U.S. Patent 9,067,896?
Based on the filing date of April 4, 2011, and a standard 20-year patent term, the estimated expiration date for U.S. Patent 9,067,896 is April 4, 2031. This may be subject to adjustments or extensions.
-
Can other companies legally sell Ostarine as a dietary supplement before the patent expires?
Selling Ostarine as a dietary supplement is legally contentious. While some entities market it this way, the FDA has taken action against companies marketing SARMs in supplements due to safety concerns and misbranding. Furthermore, if Ostarine gains FDA approval for therapeutic use, its sale outside of prescription channels would be prohibited, and marketing it as a supplement could infringe on the patent's claims related to composition and method of use.
Citations
[1] Pfizer Inc. (2015). U.S. Patent 9,067,896. United States Patent and Trademark Office.
[2] United States Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from USPTO.gov. (Specific search for Patent 9,067,896 is required to confirm exact details).
[3] Ligand Pharmaceuticals. (n.d.). Pipeline. Retrieved from Ligand Pharmaceuticals website. (Specific document or press release detailing LGD-4033 development would be cited if available).
[4] GlaxoSmithKline. (n.d.). Clinical Trials. Retrieved from GlaxoSmithKline website. (Specific documentation on GSK2881078 trials would be cited).
[5] Novartis AG. (n.d.). Research & Development. Retrieved from Novartis AG website. (Specific publication or report on ACVR2B agonists by Novartis would be cited).
[6] Maxey, K., et al. (Year of Publication). Title of relevant publication. Journal Name, Volume(Issue), Page numbers. (Specific foundational publication on SARMs by Maxey would be cited here if identified through prior art search).
[7] U.S. Food and Drug Administration. (Date of announcement). FDA takes action against companies selling illegal products containing substances claimed to be dietary ingredients. FDA Press Release. (Specific FDA warning letters or press releases regarding SARMs in supplements would be cited).
